Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis.

Leukemia - 1 Jun 2024

Li Fuhui, Qin Tiejun, Li Bing, Qu Shiqiang, Pan Lijuan, Zhang Peihong, Sun Qi, Cai Wenyu, Gao Qingyan, Jiao Meng, Li Junjie, Ai Xiaofei, Ma Jiao, Gale Robert Peter, Xu Zefeng, Xiao Zhijian

Abstract excerpt

We investigated data from 180 consecutive patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis (MDS/MPN-SF3B1-T) who were diagnosed according to the 2022 World Health Organization (WHO) classification of myeloid neoplasms to identify covariates associated with survival. At a median follow-up of 48 months (95% confidence interval [CI] 35-61 months), the median survival...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Follow-Up Studies
Share to Myelodysplastic-Myeloproliferative Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myelodysplastic Syndromes

Share to Phosphoproteins

Share to RNA Splicing Factors

Share to Serine-Arginine Splicing Factors

Share to Survival Rate

Share to Thrombocytosis

Source

Open in PubMed Open full text

Identifiers

PMID: 38714876
DOI: 10.1038/s41375-024-02262-2
PMCID: PMC11147759

Genes

SF3B1
SETBP1
SRSF2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis.PMID 38714876Read ↗

Chronic myelomonocytic leukemia with ring sideroblasts/SF3B1 mutation presents with low monocyte count and resembles myelodysplastic syndromes with-RS/SF3B1 mutation in terms of phenotype and prognosisSemantic proximity Read ↗

[Clinical Characteristics and Prognosis Analysis of MDS-RS Patients with Wild-Type SF3B1].Semantic proximity Read ↗

Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or SF3B1 Mutations: The Improved Clinical Utility of World Health Organization and International Consensus Classification 2022 Definitions, a Single-Centre Retrospective Chart Review.Semantic proximity Read ↗

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.Semantic proximity Read ↗

[Clinical features of SF3B1 mutation in patients with myelodysplastic syndrome with excess blasts].Semantic proximity Read ↗

Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: A meta-analysis.Semantic proximity Read ↗

Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS‐T) and the role of next‐generation sequencingSemantic proximity Read ↗

Clinical Characteristics and Molecular Profiling of SF3B1-Mutated Myelodysplastic Syndrome (MDS) in a Real-World Practice.Semantic proximity Read ↗

Reclassification of Myelodysplastic Neoplasms According to the 2022 World Health Organization Classification and the 2022 International Consensus Classification Using Open-Source Data: Focus on SF3B1- and TP53-mutated Myelodysplastic Neoplasms.Semantic proximity Read ↗

Integration of genomic and clinical variables improves the prediction of myelodysplastic syndromes to acute myeloid leukaemia transformation and prognosis.Semantic proximity Read ↗

[Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].Semantic proximity Read ↗

Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.